Zenotech Laboratories is currently trading at Rs. 39.20, up by 0.95 points or 2.48% from its previous closing of Rs. 38.25 on the BSE.
The scrip opened at Rs. 39.40 and has touched a high and low of Rs. 39.40 and Rs. 38.25 respectively. So far 1,210 shares were traded on the counter.
The BSE group 'XT' stock of face value Rs. 10 has touched a 52 week high of Rs. 51.80 on 15-Jun-2016 and a 52 week low of Rs. 31.50 on 30-Mar-2016.
Last one week high and low of the scrip stood at Rs. 40.95 and Rs. 38.00 respectively. The current market cap of the company is Rs. 134.96 crore.
The promoters holding in the company stood at 66.85%, while Institutions and Non-Institutions held 0.01% and 33.14% respectively.
Zenotech Laboratories has received board’s approval for winding up its Nigeria-based subsidiary ‘Zenotech Laboratories Nigeria’. The company’s board has authorised the management to take appropriate actions for initiating the process of winding up of the subsidiary.
Zenotech Laboratories is an India-based pharmaceutical company operating out of Hyderabad, India. The company is engaged in a business of manufacture and marketing of pharmaceuticals products. The company is a pharmaceutical specialty generic injectables company engaged in the area of manufacturing Oncology, bio-technology and General Injectables products.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1669.30 |
| Dr. Reddys Lab | 1234.00 |
| Cipla | 1231.50 |
| Zydus Lifesciences | 937.50 |
| Lupin | 2329.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: